Epworth Healthcare

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma6 trials
• Pancreatic cancer4 trials
• Myeloproliferative neoplasms2 trials
• Acute lymphoblastic leukaemia1 trial
• Diffuse large B-cell lymphoma1 trial
• Follicular lymphoma1 trial
• Glioblastoma1 trial
• Metastatic breast cancer1 trial
• Ovarian cancer1 trial

Phase

• Phase 37 trials
• Phase 1/25 trials
• Phase 24 trials
• Phase 11 trial

Status

• Active, not recruiting8 trials
• Recruiting7 trials
• Completed2 trials
• Terminated1 trial

Lead sponsor

• Pfizer4 trials
• Amplia Therapeutics Limited2 trials
• Daiichi Sankyo2 trials
• Arbor Research Collaborative for Health1 trial
• Cambridge University Hospitals NHS Foundation Trust1 trial
• and 8 more

Running trials

• Recruiting

  Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

  NCT07249905· Phase 1/2· ModeX Therapeutics, An OPKO Health Company· Source

  Contact: ModeX Therapeutics

• Active, not recruiting

  A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer

  NCT07026279· Phase 1/2· Amplia Therapeutics Limited· Source

• Recruiting

  Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  NCT06819007· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

  NCT05093231· Phase 2· Cambridge University Hospitals NHS Foundation Trust· Source

• Recruiting

  Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  NCT06561048· Phase 3· Corvus Pharmaceuticals, Inc.· Source

  Contact: Dr. Connie Barlas

• Active, not recruiting

  A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

  NCT06413498· Phase 3· Kite, A Gilead Company· Source

• Active, not recruiting

  A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT06425991· Phase 1· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

  NCT05623020· Phase 3· Pfizer· Source

• Active, not recruiting

  ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer

  NCT05355298· Phase 1/2· Amplia Therapeutics Limited· Source

• Recruiting

  A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

  NCT05020236· Phase 3· Pfizer· Source

• Active, not recruiting

  Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

  NCT04703192· Phase 2· Daiichi Sankyo· Source

• Active, not recruiting

  A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

  NCT04576156· Phase 3· Geron Corporation· Source

• Recruiting

  Pancreatic Cancer Early Detection Consortium

  NCT04970056· Arbor Research Collaborative for Health· Source

  Contact: Halina Pietrzak

• Recruiting

  A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

  NCT04176198· Phase 1/2· Sumitomo Pharma America, Inc.· Source

  Contact: SMPA Investigative Site

• Active, not recruiting

  Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

  NCT04195139· Phase 2· University of Sydney· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma2 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting

Closed trials

• Terminated

  A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

  NCT04735575· Phase 1/2· Shanghai EpimAb Biotherapeutics Co., Ltd.· Source

• Completed

  MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

  NCT04649359· Phase 2· Pfizer· Source

• Completed

  A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427· Phase 3· Pfizer· Source